natgillin/translations-raw huggingface dataset:
The same results were confirmed in patients that were unsuitable for other systemic therapies (see Table 1 below).
Isti rezultat je bil potrjen pri bolnikih, ki so bili neprimerni za druge sistemske terapije (glejte spodaj tabelo 1).
The same types of adverse reactions that are attributable to oral carbonic inhibitors (i.e., acid- base disturbances) may occur with topical administration (see section 4.5).
Pri njegovi topikalni uporabi se lahko torej pojavijo enake vrste neželenih učinkov, kot se pojavljajo pri uporabi peroralnih zaviralcev karboanhidraze (t.j. motnje kislinsko-bazičnega ravnovesja) (glejte poglavje 4.5).
The same volumes as for the single product should be used.
Uporabiti je treba iste količine kot za posamezno cepivo.
The same warnings and precautions apply to the elderly population.
Enaka opozorila in previdnostni ukrepi veljajo za starejšo populacijo.
The same warnings and precautions apply to the paediatric population.
Enaka opozorila in previdnostni ukrepi veljajo za pediatrično populacijo.
The sample container should be held upright and the bar-code label marked “00-minute- value” will be stuck round the sample container so that the lines of the bar code are horizontal.
Epruveto je treba držati pokonci in nanjo nalepiti črtno kodo z oznako "00-minutna vrednost" tako, da so črte v vodoravnem položaju.
The sample tubes have to be sent in the original packaging, for analysis, to a qualified laboratory.
Epruvete morate v originalni ovojnini poslati v usposobljen laboratorij, kjer jih bodo analizirali.
The Savene diluent contains potassium (98 mg/500 ml) which may be harmful to people on a low- potassium diet or who have kidney problems.
Vehikel Savene vsebuje kalij (98 mg/500 ml), ki je lahko škodljiv za osebe na dieti z nadzorovanim vnosom kalija ali bolnike z levičnimi težavami.
The Savene kit consists of Savene powder for concentrate (white to off-white powder) and Savene diluent for solution for infusion.
Komplet zdravila Savene je sestavljen iz (belega do umazano belega) praška za koncentrat Savene in vehikla za raztopino za infundiranje Savene.
The scale on the clear Cartridge Holder shows an estimate of the number of units remaining.
Lestvica na držalu insulinskega vložka prikazuje približek števila preostalih enot.
The scan uses a radioactive substance called a ‘radiopharmaceutical’ to create images.
Pri slikanju se uporablja radioaktivna snov, imenovana "radiofarmacevtski izdelek", ki omogoči nastanek posnetka.
The scanning may take place 2-4 hours after injection of NeoSpect.
Slikanje (skeniranje) je lahko 2-4 ure po injekciji NeoSpecta.
The scope and use of the Contraindicated Conditions of Use and Contraindicated Concomitant Medication checklist
Obseg in uporabo seznama pogojev, v katerih je uporaba zdravila kontraindicirana, in zdravila, katerih sočasna uporaba je kontraindicirana.
The score line is not intended for breaking the tablet.
Zareza ni namenjena za lomljenje tablet.
The score line is not intented for breaking the tablet.
Razdelilna zareza ni namenjena delitvi tablete.
The score line is only there to help you break the tablet if you have difficulty swallowing it whole.
Razdelilna zareza je namenjena le delitvi tablete za lažje požiranje in ne delitvi na enaka odmerka.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Razdelilna zareza je namenjena le delitvi tablete za lažje požiranje in ne delitvi na enaka odmerka.
The scored tablets are yellow, biconvex, capsule shaped and are engraved with ‘GX 623’ on both sides.
Rumene bikonveksne tablete v obliki kapsule z razdelilno zarezo in oznako 'GX 623' na obeh straneh.
The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Razdelilna zareza je namenjena le delitvi tablete za lažje požiranje in ne delitvi na enaka odmerka.
The sealed cartridge is included inside the administration's system housing (plastic), which also contains an internal housing (plastic) with an injection needle and a cartridge needle (both stainless steel) connected to each other by a tube (low density polyethylene and polyurethane).
Zaprt vložek je v ohišju aplikacijskega sistema (iz plastike), ki vsebuje tudi plastično notranje ohišje z injekcijsko iglo in iglo vložka (obe iz nerjavečega jekla), ki sta med seboj povezani s cevjo (iz polietilena in poliuretana nizke gostote).
The sealed plastic tray is damaged or opened.
da je zapečaten plastični ovoj poškodovan ali odprt,
The search retrieved 25 cases of paraesthesia for Optaflu.
V raziskavi je bilo odkritih 25 primerov parestezije v povezavi s cepivom Optaflu.
The Seattle Angina Questionnaire showed significant effects on several dimensions, including angina frequency (p  0.001), compared to placebo-treated patients.
Vprašalnik o angini Seattle je pokazal pomembne učinke na več razsežnosti, vključno s pogostnostjo angine (p < 0,001), v primerjavi z bolniki, ki so jih zdravili s placebom.
The second 20 mg dose should be given 4 days after transplantation.
Drugi 20- miligramski odmerek je treba bolniku dati 4 dni po presaditvi.
The second active substance, milbemycin oxime causes paralysis and death of nematodes and heartworm by interfering with the way signals are passed between nerve cells (neurotransmission) in the parasites’ nervous system.
Milbemicin oksim, druga zdravilna učinkovina, povzroča paralizo in smrt nematodov in srčnih glist, tako da vpliva na način prenosa signalov med živčnimi celicami (nevrotransmiterji) v živčnem sistemu parazitov.
The second active substance, simvastatin, belongs to the group called ‘statins’.
Druga zdravilna učinkovina, simvastatin, spada v skupino zdravil, ki jih imenujemo „statini“.
The second breath sample container is only required for mass spectrometry.
Drugi vsebnik za vzorec dihanja je potreben le za masno spektrometrijo.
The second daily dose can be taken with or without food.
Drugi dnevni odmerek lahko vzamete s hrano ali brez nje.
The second dose given between 5 and 13 months after the first dose
Cepljenje z drugim odmerkom se opravi od 5 do 13 mesecev po prvem odmerku.
The second dose is given over a period of between 15 minutes and two hours, depending on the patient’s condition.
Drugi odmerek se infundira od 15 minut do 2 uri, odvisno od stanja bolnika.
The second dose of the vaccine (V2) should be administered 4 weeks later.
Drugi odmerek cepiva (C2) moramo dati 4 tedne pozneje, kot je opisano zgoraj.
The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose.
Drugi odmerek je treba dati vsaj en mesec po prvem odmerku, tretji odmerek pa vsaj 3 mesece po drugem odmerku.
The second dose should be withheld in the event of a severe hypersensitivity reaction to Simulect or post-operative complications such as graft loss (see section 4.4).
V primeru hude preobčutljivostne reakcije na Simulect ali pooperativnih zapletov, na primer izguba presadka bolnik ne sme dobiti drugega odmerka (glejte poglavje 4.4).
The second dose should be withheld in the event of a severe hypersensitivity reaction to Simulect or post-operative complications such as graft loss (see section 4.4).
V primeru hude preobčutljivostne reakcije na Simulect ali pooperativnih zapletov, na primer izgube presadka, bolnik ne sme dobiti drugega odmerka (glejte poglavje 4.4).
The second dose should not be given before 12 weeks of age.
Drugega odmerka ne smete aplicirati pred starostjo 12 tednov.
The second dose should not be given if severe hypersensitivity reactions to Simulect or graft loss occur.
Drugega odmerka ne smemo dati, če nastopijo hude preobčutljivostne reakcije na Simulect ali izguba presadka.
The second field study showed that Vectra 3D-treated dogs had an average flea count reduction of 95% compared with 97% for the dogs treated with fipronil and (s)-methoprene.
V drugi študiji na terenu so zabeležili, da je pri psih, ki so prejeli zdravilo Vectra 3D, zmanjšanje povprečnega števila bolh znašalo 95 % v primerjavi s 97 % pri psih, ki so prejeli fipronil in (s)- metopren.
The second injection of each treatment cycle should be made approximately 2 to 3 mm apart from the first injection.
Drugo injekcijo vsakega cikla zdravljenja je treba aplicirati približno 2 do 3 mm proč od prve injekcije.
The second injection should be administered 3–4 weeks before mating.
Drugo injekcijo je treba dati 3–4 tedne pred parjenjem.
The second injection will be given no less than 28 days after the first.
Drugo injekcijo boste prejeli najmanj 28 dni po prvi.
The second injection – between 6 and 12 months after the first injection.
Druga injekcija - od 6 do 12 mesecev po prvi injekciji.
The second Japanese study showed Broadline to be 94% effective against ticks at day 30 post- treatment, compared with 91% for the fipronil and (S)-methoprene-treated cats.
Druga japonska študija je pokazala, da je zdravilo Broadline 30. dan po zdravljenju 94-odstotno učinkovito proti klopom v primerjavi z 91-odstotno učinkovitostjo pri mačkah, zdravljenih s fipronilom in (S)-metoprenom.
The second main study investigated the effects of Esmya in comparison with another medicine used to treat fibroids, leuprorelin.
V drugi glavni študiji so primerjali učinke zdravila Esmya z učinki drugega zdravila, ki se uporablja za zdravljenje leiomiomov, tj. levprorelinom.
The second major trial evaluated a maximum of 6 courses of either paclitaxel (135 mg/m² over 24 hours) followed by cisplatin (75 mg/m²) or control in over 400 patients with stage III/IV primary ovarian cancer, with a > 1 cm residual disease after staging laparotomy, or with distant metastases.
V drugem večjem preskušanju so pri več kot 400 bolnicah s primarnim rakom jajčnikov faze III/IV, z a > 1- centimetrsko osnovno boleznijo po lapratomiji ali z oddaljenimi metastazami, ocenili do 6 krogov zdravljenja s paklitakselom (135 mg/m2 v 24 urah) in nato cisplatinom (75 mg/m2) ali kontrolo.
The second paediatric, trial was a multicenter, double-blind, double-dummy, randomised, parallel group, active control, single-dose non-inferiority study, comparing intravenous palonosetron (1 mcg/kg, max 0.075 mg) versus intravenous. ondansetron.
Drugo pediatrično preskušanje je bila multicentrična, dvojno slepa, dvojno zakrita randomizirana študija ne-manjvrednosti s paralelnimi skupinami, aktivnimi kontrolami in enkratnim odmerkom, v kateri so primerjali intravenski palonosetron (1 µg/kg, največji odmerek 0,075 mg) z intravenskim ondansetronom.
The second part of this study, which lasted another 12 months, looked at the ability of Voncento to prevent bleeding episodes in 8 patients who had received Voncento during the first part of the study.
V drugem delu te študije, ki je trajal nadaljnjih 12 mesecev, so pri osmih bolnikih, ki so prejemali zdravilo Voncento v prvem delu študije, proučevali njegovo učinkovitost pri preprečevanju epizod krvavitev.
The second patch is then changed on day 15.
Drugi obliž se nato zamenja na 15. dan.
The second primary objective of the study should be the assessment of the compliance with risk minimization recommendations and the controlled access program for patients receiving Scenesse.
Drugi primarni cilj te študije je ocena upoštevanja priporočil za zmanjševanje tveganja in programa z nadzorovanim dostopom pri bolnikih, ki prejemajo zdravilo Scenesse.
The second stage of therapy is illumination with laser light 40-50 hours following injection with PhotoBarr.
Druga stopnja zdravljenja je osvetlitev z lasersko svetlobo 40-50 ur po injiciranju PhotoBarra.
The second step is the activation of Visudyne in the eye 15 minutes after the start of the infusion.
Druga stopnja je aktivacija zdravila Visudyne v očesu 15 minut po začetku infundiranja.
The second study also looked at the number of patients whose bowels opened at least twice within four hours of the first four doses.
V drugi študiji so proučevali tudi bolnike, pri katerih je do odvajanja blata prišlo vsaj dvakrat v štirih urah po prvih štirih odmerkih.
The second study also showed that M-M-RVAXPRO triggered the production of sufficient amounts of antibodies against mumps.
Druga študija je pokazala tudi, da je cepivo M-M-RVAXPRO sprožilo tvorbo zadostne količine protiteles proti mumpsu.
The second study compared Emtriva with lamivudine (another antiviral medicine) in 468 treatment-naïve adults, in combination with stavudine and either efavirenz or nevirapine (other antiviral medicines).
V drugi študiji so zdravilo Emtriva primerjali z lamivudinom (druga vrsta protivirusnega zdravila) pri 468 odraslih bolnikih, ki se pred tem še niso zdravili, in v kombinaciji s stavudinom in bodisi efavirenzom ali nevirapinom (druga vrsta protivirusnih zdravil).
The second study compared Lucentis, given on its own or as an add-on to laser photocoagulation (a treatment for diabetic macular oedema using a laser), with laser photocoagulation on its own.
V drugi študiji so zdravilo Lucentis kot samostojno zdravilo ali dopolnilno zdravljenje k laserski fotokoagulaciji (laserskemu zdravljenju makularnega edema, ki ga povzroča sladkorna bolezen) primerjali s samostojno lasersko fotokoagulacijo.
The second study compared Revlimid taken with low dose dexamethasone with standard treatment.
V drugi študiji so zdravilo Revlimid, ki je bilo vzeto z nizkim odmerkom deksametazona, primerjali s standardnim zdravljenjem.
The second study compared the effect of Tysabri with that of placebo when added to interferon beta-1a in 1,171 patients.
V drugi študiji so pri 1 171 bolnikih primerjali učinke zdravila Tysabri z učinki placeba, ki so ju dodali interferonu beta-1a.
The second study compared the effects of adding either Avastin or placebo to various chemotherapy treatments, including capecitabine, in 1,237 patients.
V drugi študiji so pri 1 237 bolnikih primerjali učinke dodajanja zdravila Avastin ali placeba k različnim vrstam kemoterapije, vključno s kapecitabinom.
The second study compared the effects of Silapo with those of Eprex/Erypo in maintaining red blood cell counts in 313 patients.
V drugi študiji so pri 313 bolnikih primerjali učinke zdravila Silapo z učinki zdravila Eprex/Erypo pri ohranjanju ravni rdečih krvnih celic.
The second study demonstrated that sevelamer carbonate powder dosed three times per day was equivalent to sevelamer hydrochloride tablets dosed three times per day in 31 hyperphosphataemic (defined as serum phosphorus levels ≥ 1.78 mmol/l) haemodialysis patients over two randomised 4 week treatment periods (mean serum phosphorus time-weighted averages were 1.6 ± 0.5 mmol/l for sevelamer carbonate powder and
Druga študija je pokazala, da so bili trije dnevni odmerki praška sevelamerijevega karbonata enakovredni trem dnevnim odmerkom tablet sevelamerijevega klorida pri 31 bolnikih s hiperfosfatemijo na hemodializi (opredeljeno kot ravni fosforja v serumu ≥ 1,78 mmol/l), zdravljenih v dveh naključnih 4-tedenskih obdobjih (srednje časovno uteženo povprečje fosforja v serumu je bilo 1,6 ± 0,5 mmol/l za prašek sevelamerijevega karbonata in
The second study demonstrated that sevelamer carbonate powder dosed three times per day was equivalent to sevelamer hydrochloride tablets dosed three times per day in 31 hyperphosphataemic (defined as serum phosphorus levels ≥ 1.78 mmol/l) haemodialysis patients over two randomised 4 week treatment periods (mean serum phosphorus time-weighted averages were 1.6 ± 0.5 mmol/l for sevelamer carbonate powder and 1.7 ±
Druga študija je pokazala, da so bili trije dnevni odmerki praška sevelamerijevega karbonata enakovredni trem dnevnim odmerkom tablet sevelamerijevega klorida pri 31 bolnikih s hiperfosfatemijo na hemodializi (opredeljeno kot ravni fosforja v serumu ≥ 1,78 mmol/l), zdravljenih v dveh naključnih 4-tedenskih obdobjih (srednje časovno uteženo povprečje fosforja v serumu je bilo 1,6 ± 0,5 mmol/l za prašek sevelamerijevega karbonata in
The second study enrolled 22 patients with invasive candidiasis including candidaemia (ICC), and esophageal candidiasis (EC) requiring either primary or salvage therapy, of whom
V drugo študijo so vključili 22 bolnikov z invazivno kandidozo, vključno s kandidemijo (ICC – Invasive candidiasis including candidaemia), in kandidozo požiralnika (EC – Esophageal candidiasis), ki zahteva primarno ali rešilno zdravljenje, od katerih so
The second study enrolled 22 patients with invasive candidiasis including candidaemia (ICC), and esophageal candidiasis (EC) requiring either primary or salvage therapy, of whom 17 were included in the MITT efficacy analyses.
V drugo študijo so vključili 22 bolnikov z invazivno kandidozo, vključno s kandidemijo (ICC – Invasive candidiasis including candidaemia), in kandidozo požiralnika (EC – Esophageal candidiasis), ki zahteva primarno ali rešilno zdravljenje, od katerih so 17 bolnikov vključili v analize učinkovitosti MITT.
The second study established that Aflunov should be given as two doses at least three weeks apart.
Druga študija je potrdila, da je treba cepivo Aflunov dati z dvema odmerkoma v presledku vsaj treh tednov.
The second study examined the effects of emtricitabine and tenofovir disoproxil, taken with lopinavir and ritonavir (other antiviral medicines) in 196 patients with HIV-1 infection.
V drugi študiji so proučevali učinke jemanja emtricitabina in tenofovir dizoproksila skupaj z lopinavirjem in ritonavirjem (drugima protivirusnima zdraviloma) pri 196 bolnikih z okužbo z virusom HIV-1.
The second study included 118 adults who had taken another protease inhibitor in the past and compared Kaletra capsules with a protease inhibitor chosen by the study investigator on a patient-by-patient basis.
Druga študija, v kateri so primerjali kapsule Kaletra z zaviralcem proteaz, ki ga je izbral raziskovalec za vsakega posameznega bolnika, je vključevala 118 odraslih, ki so v preteklosti prejemali drug zaviralec proteaz.
The second study included a dose range of 2.0 mg/m2 to mg/m2 in children (n = 8), adolescents (n = 3), and young adults (n = 3) with leukaemia.
V drugi študiji so otroci (n = 8), mladostniki (n = 3) in mlajši odrasli (n = 3) z levkemijo prejemali odmerek od 2,0 mg/m2 do 5,2 mg/m2.
The second study included a total of 119 patients whose disease was in the ‘accelerated phase’, four fifths of whom had stopped responding to imatinib.
V drugo študijo je bilo vključenih skupaj 119 bolnikov, katerih bolezen je bila v pospešeni fazi in katerih štiri petine se niso več odzivale na imatinib.
The second study involved 1,088 men with metastatic prostate cancer who had either no or only mild symptoms of the disease and for whom castration treatment had not worked or no longer work.
V drugo študijo je bilo vključenih 1 088 moških z metastatskim rakom prostate, ki niso imeli simptomov bolezni ali pa so bili ti zgolj blagi in pri katerih zdravljenje s kastracijo ni bilo uspešno oziroma je prenehalo delovati.
The second study involved 1,286 women who had been through the menopause with metastatic breast cancer that was sensitive to hormones.
V drugo študijo je bilo vključenih 1 286 žensk po menopavzi, ki so imele metastatski rak dojke, občutljiv na hormone.
The second study involved 1,901 men with prostate cancer which did not respond to hormonal treatment.
V drugi študiji je sodelovalo 1 901 moških z rakom prostate, ki se niso odzvali na hormonsko zdravljenje.
The second study involved 177 patients aged from 2 to 20 years and had two parts: in the first part, all patients were given an injection of Ilaris every four weeks for a maximum of 32 weeks.
Druga študija je vključevala 177 bolnikov, starih od 2 do 20 let, in je potekala v dveh delih: v prvem delu so vsi bolniki prejeli injekcijo zdravila Ilaris vsake štiri tedne, kar je trajalo največ 32 tednov.
The second study involved 20 patients with aHUS who were already receiving plasma exchange or infusion.
Druga študija je vključevala 20 bolnikov z atipičnim hemolitično-uremičnim sindromom, ki so že prejemali izmenjavo plazme ali infuzijo.
The second study involved 32 patients aged 12 years and above who were given Nuwiq to prevent and treat bleeding events as well as to prevent bleeding during surgery.
V drugi študiji je sodelovalo 32 bolnikov, starih 12 let ali več, ki so jim dajali zdravilo Nuwiq za preprečevanje in zdravljenje krvavitev ter za preprečevanje krvavitve med kirurškim posegom.
The second study involved 383 adults who had experienced a single attack of demyelination and compared the ability of Avonex and placebo to reduce the risk of a second attack.
Druga študija je vključevala 383 odraslih, ki so doživeli en demielinizacijski napad, v njej pa so primerjali sposobnost zdravila Avonex pri zmanjševanju tveganja za pojav drugega napada v primerjavi s placebom.
The second study involved 410 patients with advanced well- or moderately differentiated neuroendocrine tumours of pancreatic origin.
Druga študija je vključevala 410 bolnikov z napredovalim zelo ali zmerno diferenciranim nevroendokrinim tumorjem pankreatičnega izvora.
The second study involved 413 patients whose blood glucose was not adequately controlled by insulin and metformin with or without other diabetes medicines taken by mouth.
V drugo študijo je bilo vključenih 413 bolnikov, pri katerih raven glukoze v krvi ni bila zadostno nadzorovana z insulinom in metforminom ne glede na to, ali so jemali druga zdravila za peroralno uporabo za zdravljenje sladkorne bolezni, ali jih niso.
The second study involved 42 children with short bowel syndrome who needed parenteral nutrition.
V drugo študijo je bilo vključenih 42 otrok s sindromom kratkega črevesa, ki so potrebovali parenteralno prehrano.
The second study involved 507 patients and measured effectiveness by how many patients had disease that got worse during treatment.
V drugi študiji, v kateri je sodelovalo 507 bolnikov, so učinkovitost merili na podlagi števila bolnikov, pri katerih se je bolezen med zdravljenjem poslabšala.
The second study involved 576 adults and adolescents given Nucala every 4 weeks for 28 weeks.
Druga študija je zajela 576 odraslih in mladostnikov, ki so 28 tednov enkrat na štiri tedne prejemali zdravilo Nucala.
The second study involved 62 patients who still had their spleens and who had been treated for ITP in the past.
V drugo študijo je bilo vključenih 62 bolnikov, ki so še vedno imeli vranico in so se v preteklosti že zdravili zaradi imunske trombocitopenične purpure.
The second study involved 938 adults aged 70 years or older who had already been vaccinated against invasive disease caused by S. pneumoniae at least five years earlier.
V drugo študijo je bilo vključenih 938 odraslih, starih 70 let ali več, ki so pred najmanj petimi leti že bili cepljeni proti invazivni bolezni, ki jo povzroča bakterija
The second study looked at 405 advanced melanoma patients whose disease had got worse despite previous treatment with a cancer medicine.
Druga študija je proučevala 405 bolnikov z napredovalim melanomom, pri katerih se je bolezen poslabšala kljub prejšnjemu zdravljenju z zdravilom za zdravljenje raka.
The second study looked at using Privigen for immunomodulation in 57 patients with ITP.
V drugi študiji so proučevali uporabo zdravila Privigen za imunomodulacijo pri 57 bolnikih z idiopatsko trombocitopenično purpuro.
The second study looked at whether Aprovel increased the time taken until the patients’ blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died.
V drugi študiji so preučevali, ali zdravilo Aprovel podaljša čas, v katerem se raven kreatinina (označevalca ledvičnega obolenja) v krvi bolnikov podvoji, čas do pojava potrebe po presaditvi ledvic ali dializi oziroma čas do nastopa smrti.
The second study looked at whether Irbesartan BMS increased the time taken until the patients’ blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died.
Druga študija je proučevala, ali zdravilo Irbesartan BMS podaljša čas, v katerem se raven kreatinina v krvi (označevalca ledvične bolezni) pri bolnikih podvoji, ali čas do pojava potrebe po presaditvi ledvic ali dializi oziroma do nastopa smrti.